Abstract | PURPOSE: As protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion. METHODS: A prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster. RESULTS: Among 110 participants,56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25-11.67) folds and 2.40 (95 %CI 1.90-3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5-79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1-34.7) fold in and immunocompetent group, was observed. CONCLUSION: A third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals.
|
Authors | Shirley Shapiro Ben David, Barak Mizrahi, Daniella Rahamim-Cohen, Lia Supino-Rosin, Arnon Shahar, Sharon Hermoni-Alon, Ariela Fremder Sacerdote, Angela Irony, Rachel Lazar, Nir Kalkstein, Yaniv Lustig, Victoria Indenbaum, Daniel Landsberger, Miri Mizrahi-Reuveni, Shirley Shapira |
Journal | Vaccine
(Vaccine)
Vol. 40
Issue 30
Pg. 4038-4045
(06 26 2022)
ISSN: 1873-2518 [Electronic] Netherlands |
PMID | 35641358
(Publication Type: Journal Article, Observational Study)
|
Copyright | Copyright © 2022 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Viral
- Immunoglobulin G
- Vaccines
- BNT162 Vaccine
|
Topics |
- Antibodies, Viral
- Antibody Formation
- BNT162 Vaccine
- COVID-19
(prevention & control)
- Female
- Humans
- Immunoglobulin G
- Longitudinal Studies
- Male
- Middle Aged
- Prospective Studies
- SARS-CoV-2
- Vaccines
|